[{"orgOrder":0,"company":"PharmaBiome","sponsor":"Ferring Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Gastroenterology","graph2":"Discovery","graph3":"PharmaBiome","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PharmaBiome \/ Ferring Pharmaceuticals","highestDevelopmentStatusID":"2","companyTruncated":"PharmaBiome \/ Ferring Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by PharmaBiome

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
filter

Year

filter

DEALS // DEV.

filter

Country

filter
Sponsor
filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

Therapeutic Area by Lead Product

ForexGraph

Study Phase by Lead Product

ForexGraph

Company by Lead Product

ForexGraph

Top Deals by Deal Size (USD bn)

ForexGraph

01

Peptide Therapy Summit
Not Confirmed
Peptide Therapy Summit
Not Confirmed

Details : Under the collaboration, Ferring will get exclusive rights to develop, manufacture and commercialise next generation microbiome-based therapeutics within the field of gastroenterology arising out of the collaboration.

Product Name : Undisclosed

Product Type : Undisclosed

Upfront Cash : Undisclosed

November 12, 2023

Lead Product(s) : Undisclosed

Therapeutic Area : Gastroenterology

Highest Development Status : Discovery

Sponsor : Ferring Pharmaceuticals

Deal Size : Undisclosed

Deal Type : Licensing Agreement

blank